104 related articles for article (PubMed ID: 1559570)
21. IFN-beta induced biochemical and immunological modifications in hairy cell leukemia patients.
Liberati AM; Schippa M; Portuesi MG; Grazia Proietti M; De Angelis V; Ferrajoli A; Cinieri S; Di Clemente F; Palmisano L; Berruto P
Haematologica; 1991; 76(5):375-82. PubMed ID: 1806440
[TBL] [Abstract][Full Text] [Related]
22. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma.
Nanbo A; Inoue K; Adachi-Takasawa K; Takada K
EMBO J; 2002 Mar; 21(5):954-65. PubMed ID: 11867523
[TBL] [Abstract][Full Text] [Related]
23. Cytokine modulation of costimulatory molecules on human fetal retinal pigment epithelial cells.
Farrokh-Siar L; Rezai KA; Palmer EM; Patel SC; Ernest TJ; van Seventer GA
Curr Eye Res; 2001 Oct; 23(4):285-90. PubMed ID: 11852430
[TBL] [Abstract][Full Text] [Related]
24. Leukemic cells in hairy cell leukemia and B cell chronic lymphocytic leukemia release soluble TNF receptors.
Trentin L; Pizzolo G; Zambello R; Agostini C; Morosato L; Sancetta R; Adami F; Vinante F; Chilosi M; Gallati H
Leukemia; 1995 Jun; 9(6):1051-5. PubMed ID: 7596168
[TBL] [Abstract][Full Text] [Related]
25. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
26. Autocrine loop of tumor necrosis factor induced by interferon-alpha in tumor cells from hairy cell leukemia.
Romquin N; Billard C
Leukemia; 1995 Jan; 9(1):87-94. PubMed ID: 7845033
[TBL] [Abstract][Full Text] [Related]
27. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
28. Human recombinant interferon alpha-2C enhances the expression of class II HLA antigens on hairy cells.
Baldini L; Cortelezzi A; Polli N; Neri A; Nobili L; Maiolo AT; Lambertenghi-Deliliers G; Polli EE
Blood; 1986 Feb; 67(2):458-64. PubMed ID: 2935210
[TBL] [Abstract][Full Text] [Related]
29. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray.
Belov L; de la Vega O; dos Remedios CG; Mulligan SP; Christopherson RI
Cancer Res; 2001 Jun; 61(11):4483-9. PubMed ID: 11389079
[TBL] [Abstract][Full Text] [Related]
30. On the mechanism of action of interferons: interaction with nonsteroidal anti-inflammatory agents, pentoxifylline (Trental) and cGMP inducers.
Aszalos A; Grimley PM; Balint E; Chadha KC; Ambrus JL
J Med; 1991; 22(4-5):255-71. PubMed ID: 1664849
[TBL] [Abstract][Full Text] [Related]
31. Interferon-alpha downregulates the abnormal intracytoplasmic free calcium concentration of tumor cells in hairy cell leukemia.
Génot E; Bismuth G; Degos L; Sigaux F; Wietzerbin J
Blood; 1992 Oct; 80(8):2060-5. PubMed ID: 1382718
[TBL] [Abstract][Full Text] [Related]
32. IFN-alpha sensitizes daudi B lymphoma cells to anti-IgM induced loss of mitochondrial membrane potential through activation of c-Jun NH(2)-terminal kinase.
Hayashida M; Hoshika A; Kanetaka Y; Yanase N; Mizuguchi J
J Interferon Cytokine Res; 2006 Jun; 26(6):421-9. PubMed ID: 16734563
[TBL] [Abstract][Full Text] [Related]
33. Ultrastructural, immunologic and clinical follow-up of five patients with HCL treated with interferon (IFN) for more than three years.
Mantovani G; Astara G; Curreli L; Lai P; Turnu E; Locci F; Lantini MS; Cossu M; Riva A; Del Giacco GS
Haematologica; 1992; 77(4):326-35. PubMed ID: 1427443
[TBL] [Abstract][Full Text] [Related]
34. Comparison of adhesion mechanisms and surface protein expression in CD77-positive and CD77-negative Burkitt's lymphoma cells.
Jackson T; Van Exel C; Reagans K; Verret R; Maloney M
Cell Mol Biol (Noisy-le-grand); 2001 Nov; 47(7):1195-200. PubMed ID: 11838967
[TBL] [Abstract][Full Text] [Related]
35. Establishment and characterization of a new human Burkitt's lymphoma cell line (WSU-BL).
Mohamed AN; Mohammad RM; Koop BF; al-Katib A
Cancer; 1989 Sep; 64(5):1041-8. PubMed ID: 2527086
[TBL] [Abstract][Full Text] [Related]
36. RAB-1: a new monoclonal antibody to leukemic hairy cells.
Berrebi A; Eshhar Z; Linder S; Guedj L; Avraham H
Leuk Res; 1986; 10(9):1071-8. PubMed ID: 3531732
[TBL] [Abstract][Full Text] [Related]
37. Expression of surface antigens during the cell cycle in different growth phases of American and African Burkitt's lymphoma cell lines.
Sieverts H; Alabaster O; Goldschmidts W; Magrath I
Cancer Res; 1986 Mar; 46(3):1182-8. PubMed ID: 3080238
[TBL] [Abstract][Full Text] [Related]
38. Interferon alpha-induced modulation of leukocyte cell surface antigens: immunocytofluorometric study with human leukaemia/lymphoma cell lines.
Chorváth B; Sedlák J; Fuchsberger N
Acta Virol; 1991 Jan; 35(1):7-18. PubMed ID: 1683118
[TBL] [Abstract][Full Text] [Related]
39. An interferon resistant variant of the hairy-cell leukemic cell line, Eskol: biochemical and immunological characterization.
Ozes ON; Klein SB; Reiter Z; Taylor MW
Leuk Res; 1993 Nov; 17(11):983-90. PubMed ID: 7694002
[TBL] [Abstract][Full Text] [Related]
40. The expansion of human gammadelta T cells in response to Daudi cells requires the participation of CD4+ T cells.
Fayen JD; Tykocinski ML
Immunology; 1999 Jun; 97(2):272-9. PubMed ID: 10447742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
